291 related articles for article (PubMed ID: 24104479)
1. A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities.
Vizeacoumar FJ; Arnold R; Vizeacoumar FS; Chandrashekhar M; Buzina A; Young JT; Kwan JH; Sayad A; Mero P; Lawo S; Tanaka H; Brown KR; Baryshnikova A; Mak AB; Fedyshyn Y; Wang Y; Brito GC; Kasimer D; Makhnevych T; Ketela T; Datti A; Babu M; Emili A; Pelletier L; Wrana J; Wainberg Z; Kim PM; Rottapel R; O'Brien CA; Andrews B; Boone C; Moffat J
Mol Syst Biol; 2013 Oct; 9():696. PubMed ID: 24104479
[TBL] [Abstract][Full Text] [Related]
2. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
[TBL] [Abstract][Full Text] [Related]
3. Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Marcotte R; Brown KR; Suarez F; Sayad A; Karamboulas K; Krzyzanowski PM; Sircoulomb F; Medrano M; Fedyshyn Y; Koh JLY; van Dyk D; Fedyshyn B; Luhova M; Brito GC; Vizeacoumar FJ; Vizeacoumar FS; Datti A; Kasimer D; Buzina A; Mero P; Misquitta C; Normand J; Haider M; Ketela T; Wrana JL; Rottapel R; Neel BG; Moffat J
Cancer Discov; 2012 Feb; 2(2):172-189. PubMed ID: 22585861
[TBL] [Abstract][Full Text] [Related]
4. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer.
Cheung HW; Cowley GS; Weir BA; Boehm JS; Rusin S; Scott JA; East A; Ali LD; Lizotte PH; Wong TC; Jiang G; Hsiao J; Mermel CH; Getz G; Barretina J; Gopal S; Tamayo P; Gould J; Tsherniak A; Stransky N; Luo B; Ren Y; Drapkin R; Bhatia SN; Mesirov JP; Garraway LA; Meyerson M; Lander ES; Root DE; Hahn WC
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12372-7. PubMed ID: 21746896
[TBL] [Abstract][Full Text] [Related]
5. Network controllability solutions for computational drug repurposing using genetic algorithms.
Popescu VB; Kanhaiya K; Năstac DI; Czeizler E; Petre I
Sci Rep; 2022 Jan; 12(1):1437. PubMed ID: 35082323
[TBL] [Abstract][Full Text] [Related]
6. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.
Zhao D; Lu X; Wang G; Lan Z; Liao W; Li J; Liang X; Chen JR; Shah S; Shang X; Tang M; Deng P; Dey P; Chakravarti D; Chen P; Spring DJ; Navone NM; Troncoso P; Zhang J; Wang YA; DePinho RA
Nature; 2017 Feb; 542(7642):484-488. PubMed ID: 28166537
[TBL] [Abstract][Full Text] [Related]
7. Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents.
McCormick A; Earp E; Leeson C; Dixon M; O'Donnell R; Kaufmann A; Edmondson RJ
Int J Gynecol Cancer; 2016 May; 26(4):632-9. PubMed ID: 26905328
[TBL] [Abstract][Full Text] [Related]
8. FGMD: A novel approach for functional gene module detection in cancer.
Jin D; Lee H
PLoS One; 2017; 12(12):e0188900. PubMed ID: 29244808
[TBL] [Abstract][Full Text] [Related]
9. Piwi-interacting RNA-651 promotes cell proliferation and migration and inhibits apoptosis in breast cancer by facilitating DNMT1-mediated PTEN promoter methylation.
Liu T; Wang J; Sun L; Li M; He X; Jiang J; Zhou Q
Cell Cycle; 2021 Aug; 20(16):1603-1616. PubMed ID: 34313525
[TBL] [Abstract][Full Text] [Related]
10. PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors.
Mahmood SF; Gruel N; Nicolle R; Chapeaublanc E; Delattre O; Radvanyi F; Bernard-Pierrot I
Am J Pathol; 2013 Nov; 183(5):1634-1644. PubMed ID: 24051013
[TBL] [Abstract][Full Text] [Related]
11. Isogenic human mammary epithelial cell lines: novel tools for target identification and validation. Comprehensive characterization of an isogenic human mammary epithelial cell model provides evidence for epithelial-mesenchymal transition.
Ulbricht U; Sommer A; Beckmann G; Lutzenberger M; Seidel H; Kreft B; Toschi L
Breast Cancer Res Treat; 2013 Apr; 138(2):437-56. PubMed ID: 23483306
[TBL] [Abstract][Full Text] [Related]
12. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.
Wang H; Han H; Von Hoff DD
Cancer Res; 2006 Oct; 66(19):9722-30. PubMed ID: 17018631
[TBL] [Abstract][Full Text] [Related]
13. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
Mills GB; Lu Y; Fang X; Wang H; Eder A; Mao M; Swaby R; Cheng KW; Stokoe D; Siminovitch K; Jaffe R; Gray J
Semin Oncol; 2001 Oct; 28(5 Suppl 16):125-41. PubMed ID: 11706404
[TBL] [Abstract][Full Text] [Related]
14. Enhanced immortalization, HUWE1 mutations and other biological drivers of breast invasive carcinoma in Black/African American patients.
Andey T; Attah MM; Akwaaba-Reynolds NA; Cheema S; Parvin-Nejad S; Acquaah-Mensah GK
Gene; 2020 Dec; 763S():100030. PubMed ID: 34493366
[TBL] [Abstract][Full Text] [Related]
15. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
Zhang L; Ma T; Brozick J; Babalola K; Budiu R; Tseng G; Vlad AM
Oncogene; 2016 Sep; 35(38):5010-20. PubMed ID: 26973247
[TBL] [Abstract][Full Text] [Related]
16. Relevant genomics of neurotensin receptor in cancer.
Elek J; Pinzon W; Park KH; Narayanan R
Anticancer Res; 2000; 20(1A):53-8. PubMed ID: 10769634
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Rauh-Adelmann C; Lau KM; Sabeti N; Long JP; Mok SC; Ho SM
Mol Carcinog; 2000 Aug; 28(4):236-46. PubMed ID: 10972993
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of selected histone modifier genes in human solid cancers.
Ozdağ H; Teschendorff AE; Ahmed AA; Hyland SJ; Blenkiron C; Bobrow L; Veerakumarasivam A; Burtt G; Subkhankulova T; Arends MJ; Collins VP; Bowtell D; Kouzarides T; Brenton JD; Caldas C
BMC Genomics; 2006 Apr; 7():90. PubMed ID: 16638127
[TBL] [Abstract][Full Text] [Related]
19. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
Liu C; Zhao J; Lu W; Dai Y; Hockings J; Zhou Y; Nussinov R; Eng C; Cheng F
PLoS Comput Biol; 2020 Feb; 16(2):e1007701. PubMed ID: 32101536
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of epithelial ovarian cancer reveals key genes and pathways associated with chemotherapy resistance.
Zhang M; Luo SC
Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
